Antiviral activity of nucleoside analogues during short-course monotherapy or dual therapy: Its role in preventing HIV infection in infants

Journal of Acquired Immune Deficiency Syndromes

Volumn 42, Issue 2, 2006, Pages 169-176

  Gray, Glenda ^a,c   Violari, Avye ^a   McIntyre, James ^a   Jivkov, Boris ^a   Schnittman, Steven ^b   Reynolds, Laurie ^b   Ledeine, Jean Marie ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b BRISTOL MYERS SQUIBB   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Antiviral activity; HIV AIDS; Mother to child transmission

Indexed keywords

DIDANOSINE; NUCLEOSIDE ANALOG; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BIRTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIVERY; DISEASE TRANSMISSION; DRUG ERUPTION; FATTY LIVER; FEMALE; GASTROENTERITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INFANT; INFECTION; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; MOTHER; PNEUMONIA; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOUTH AFRICA; VAGINITIS; WASTING SYNDROME;

ACIDOSIS, LACTIC; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DISEASE TRANSMISSION, VERTICAL; DRUG THERAPY, COMBINATION; FATTY LIVER; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; MALE; MOTHERS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; RNA, VIRAL; SOUTH AFRICA; STAVUDINE; VIRAL LOAD; ZIDOVUDINE;

EID: 33745111820     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000219772.74432.20     Document Type: Article

References (20)

1. Mofenson LM, Wolinsky SM. Vertical transmission of HIV. Part C: current insights regarding vertical transmission. In: Pizzo PA, Wilfert CM eds. Pediatric AIDS: The Challenge of HIV Infection in Infants, Children, and Adolescents. Baltimore, MD: Williams and Wilkins, 1994:179-203.
2. Mofenson LM, Lambert JS, Stiehm ER, et alPACTG Study 185 Team. Risk factors for perinatal transmission of human immunodeficiency virus type-1 in women treated with zidovudine. N Engl J Med. 1999;341(6):441-443.
3. Leroy V, Montcho C, Manigart O, et al. Maternal plasma viral load, zidovudine and mother-to-child transmission of HIV-1 in Africa. Ditrame ANRS 049a trial. AIDS. 2001;15(4):517-522.
4. Dickover RE, Garratty EM, Herman SA, et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternal zidovudine treatment on viral load. JAMA. 1996;275(8):640-641.
5. Boyer PJ, Dillon M, Navaie M, et al. Factors predictive of maternal-fetal transmission of HIV-1. Preliminary analysis of zidovudine given during pregnancy and/or delivery. JAMA. 1994;271(24):1925-1930.
6. Garcia PM, Kalish LA, Pitt J, et alWomen and Infants Transmission Study Group. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med. 1999;341:394-402.
7. Connor EM, Sperling RS, Gelber R, et alPediatric AIDS Clinical Trials Group Protocol 076 Study Group. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331(18):1173-1180.
8. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med. 1996;335(22):1621-1629.
9. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med. 2002;346(24):1863-1870.
10. O'Sullivan MJ, Boyer PJ, Scott GB, et al. Zidovudine Collaborative Working Group. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Am J Obstet Gynecol. 1993;168:1510-1516.
11. Wang Y, Livingston E, Patil S, et al. Pharmacokinetics of didanosine in antepartum and post-partum human immunodeficiency virus-infected women and their neonates: an AIDS clinical trials study. J Infect Dis. 1999;180:1536-1541.
12. Odinecs A, Nosbisch C, Keller RD, et al. In vivo maternal-fetal pharmacokinetics of stavudine (2,3-didehydro-3-deoxythymidine) in pigtailed macaques (Macaca nemestrina). Antimicrob Agents Chemother. 1996;40:196-202.
13. Kline MW, Dunkle LM, Church JA, et al. A Phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics. 1995;96:247-252.
14. Rongkavilt C, Thaithumyanon P, Chuenyam T, et al. Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates. Antimicrob Agents Chemother. 2001;45:3585-3590.
15. Fleming TR. One sample multiple testing procedure for phase II clinical trials. Biometrics. 1982;38(1):143-151.
16. Gray GE, Urban M, Chersich MF, et al. A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. AIDS. 2005;19(12):1289-1297.
17. World Health Organization. Antiretroviral drugs and the prevention of mother-to-child transmission of HIV infection in resource-limited settings. Expert consultation, Geneva, Switzerland, February 5-6, 2004. Available at: www.who.int/hiv/pub/mtct/en/arvdrugswomenguidelinesfinal.
18. Alimenti A, Burdge DR, Ogilvie GS, et al. Lactic acidemia in human immune deficiency virus uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J. 2003;22:782-789.
19. Wade NA, Unadkat JD, Huang S, et al. Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. J Infect Dis. 2004;190:2167-2174.
20. Bristol-Myers Squibb Co Healthcare Providers. Important Drug Warning Letter. Wallingford, CT: Bristol-Myers Squibb; 2001.